傅盟医药咨询(上海)有限公司

Pharmerit (Shanghai) Company Limited

Pharmerit International是一家在全球范围进行卫生经济与结果研究(Health Economics Outcomes Research,HEOR)以及市场准入策略的国际咨询公司。Pharmerit International全球现有100多位研究人员,分布于北美、欧洲、和亚太的6个国家和地区。

我们的使命是 “通过证据研究改善患者对医疗服务的获取在全球范围。我们所进行的HEOR研究可以为制药企业、生物技术公司、医疗器械公司、医疗诊断公司,以及与医疗卫生相关的政府机构或其他民间组织的决策者提供地方的、国家的、或国际层面的证据信息。

Pharmerit International及其所属的傅盟医药咨询是由在卫生经济与结果研究和市场准入领域内极富创造力、经验丰富、并以解决问题为导向的专家组成。我们共有四个相关联的卓越中心,通过这四个中心来帮助我们的客户定义、构建和传达其产品的临床、人文和经济价值。 这四个中心分别如下:

Asia-Pacific Experience

  • Modeling, trial HE analysis, hospital database studies, KOL interviews, and workshops in oncology, infectious disease, CVD, RA/OA, RCC, and mental diseases
  • Chart review studies in NSCLC with an EGFR exon 20 insertion mutation, RA pain (with PRO), CVD, and infectious disease
  • Antimicrobial stewardship program evaluations (survey, model, & GUI ipad Apps)
  • Literature reviews & critiques (e.g., burden of heart failure, stroke, MI, diabetes, dialysis)
  • Market access projects such as value dossiers, value messages and decks, storyboards, access challenge compendium for CVD, RA, infection diseases, and orphan drugs
  • Generics strategy in emerging markets incl. China
  • Policy makers’ view of h. zoster vaccine
  • Training modules and workshops
  • Medical communication support
  • Local connections with universities, hospitals, physicians, medical insurance/hospital database vendors, policy decision-makers, and other stakeholders
  • National BIM and CEA of dyslipidemia treatment
  • Leukemia therapy dossier for HIRA
  • CE of bisphosphonates
  • Orphan drug value dossier
  • Market analysis of IV antiplatelet agent
  • BOI literature review for VTE among Indian women taking oral contraceptives
  • Physician online surveys for brand and generic product use in glaucoma
  • Patient journey study for prostate cancer
  • Epidemiology and burden of 4 hepatic conditions in Japan (JMDC)
  • Disease burden and treatment pattern for RSV infection (JMDC)
  • Model adaptations and literature reviews for Japan in various indications
  • AML Strategic literature review and HTA recommendation
  • NHRD database study on AF treatment and stroke prevention
  • HRQoL & cost evaluations for various cancers
    Micro-simulation modeling for lupus
  • P&R and Market Access strategy consulting for a hyponatremia product
  • P&R submissions for a new NSCLC drug
  • P&R submissions for a nutrition regimen indicated to patients in hypercatabolic &/or hypermetabolic states together w/ parenteral or enteral nutrition
  • A chart review study to assess the economic/clinical burden of varicella in pediatric and adults patients in 4 countries (starting with Thailand)
    Systematic literature reviews of the epidemiology of recurrence, years of life lost and mortality, and economic burden of Myocardial Infarction and stroke in the JAPAC Region (for 8 Asia-Pacific countries)
  • A CVD chart review study in China, South Korea and Thailand
  • An osteoarthritis pain chart review and PRO survey study in China, Philippine, Russia, and Thailand
  • An online physician survey to assess real-world treatment pattern of pain, agitation, and delirium (PAD) in the APAC Region (Korea, Australia, Malaysia, Taiwan, and Singapore)
  • National BIM for the new AHA dyslipidemia management guideline in Korea, Taiwan, Thailand, and Malaysia
  • Economics of atopic dermatitis in China, Singapore, Indonesia, Malaysia
  • HTA road map for 8 Asia-Pacific countries
Dossiers
Chinese value dossiers for new Hep C product and existing arthritis pain product

    • Literature searches were conducted to identify references published and to address data gaps in China
    • An executive summary outlining the value messages and supporting evidence was included as part of the dossier

Value Decks and Other MA Communication ToolsDeveloped 5+ value decks and value brief (as HTA submission form) for products in hypertension, hyperlipidemia, infectious disease, rheumatoid arthritis, and dry eye to support the need of marketing, market access, medical, government affair, and other internal stakeholders

    • Target literature reviews were conducted
    • Verification of evidence in the existing materials, such as GVD, was also conducted
    • The value decks contained the key messages, evidence, key storyline, etc.

Developed Value Story Board, Objection handlers, value story videos, and various market access materials for oncology product, hyperlipidemia, antifungals, and antibiotics.

Developed a GUI tool to demonstrate budget impact for a new Hep C product

Case Study

Please get in touch

To learn more about our research and discuss what we could do for you, please get in touch.

Cindy Gao

Asia-Pacific Regional Lead

Email »

Office (USA): +1-240-821-1266

Office (China): +86 21 5353 7099